13001 East 17th Place
Aurora, CO 80045
AURORA, Colo. (August 16, 2010) – The University of Colorado Hospital Foundation (UCHF) has announced a campaign to raise $20 million for the expansion of University of Colorado Cancer Center (UCCC). Since the University of Colorado Hospital’s (UCH) clinical services for cancer relocated to the Anschutz Medical Campus in November 2000, demand has nearly doubled.
By Erika Matich | University Communications
As oncologists already know and newly diagnosed lung cancer patients learn, the kind of treatment given to patients is increasingly becoming dependent on the specific gene mutation present in the cancer. But, as lung cancer moves from being one common disease to multiple different diseases at the molecular level, learning about and getting access to the right treatment within clinical trials can be challenging for these subpopulations of patients that may be widely dispersed around the globe.
Different kinds of lung cancer behave in different ways, suggesting they are fundamentally different diseases. According to a University of Colorado Cancer Center study published in Cancer, the official journal of the American Cancer Society, different subgroups of non-small cell lung cancer (NSCLC) show distinct patterns of spread in the body.
Within many hormone-receptor positive breast cancers lives a subpopulation of receptor-negative cells – knock down the hormone-receptor positive cells with anti-estrogen drugs and you may inadvertently promote tumor takeover by more dangerous, receptor-negative cells.
University of Colorado Cancer Center is looking for cancer survivors to take part in a clinical trial of a program aimed at helping them manage their condition more effectively. The program, called “Cancer: Thriving and Surviving,” is adapted from a successful effort helping people manage other chronic conditions like diabetes.
Results from the National Lung Screening Trial, published today in the New England Journal of Medicine, show that patients who receive low-dose computerized tomography (LDCT) scans once per year for three years to detect lung cancer experience a 20 percent lower risk of death from lung cancer than those who are screened using standard chest X-rays. This finding led National Cancer Institute (NCI) investigators to halt the study early and release results.
A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest group of patients to take it within the first of these clinical trials are being presented at the annual meeting of the American Society of Clinical Oncology (ASCO).
A discovery at University of Colorado Cancer Center shows testing lung cancer on a molecular level can produce new insights into this deadly disease.
The American Cancer Society today launched its Patient Navigator Program at the University of Colorado Cancer Center, thanks to support received from AstraZeneca. This is the 4th Patient Navigator Program site, and the 4th in Colorado as part of a strategic nationwide effort to significantly extend the reach of this innovative program and assist individual cancer patients in negotiating the health care system.
New therapies for people with Alzheimer’s disease could be the result of an important study at the University of Colorado Denver School of Medicine. The study shows a brain protein that plays a key role in cognitive function and removal of toxins is inhibited in the brains of people with Alzheimer’s.